Table 1. Baseline characteristics of the study population.
| Patients ID | Age | BMI (kg/m2) | Dose (mg) | HPV16 infection | Cytology | Histology | RCI grading | |
|---|---|---|---|---|---|---|---|---|
| Phase 1 | ||||||||
| 1-1 (A0201) | 26 | 17.31 | 500 | + | HSIL | CIN 3 | 7 | |
| 1-2 (A0401) | 35 | 22.52 | 500 | + | ASC-H | CIN 3 | 5 | |
| 1-3 (A0402) | 24 | 17.58 | 500 | + | LSIL | CIN 3 | 5 | |
| 1-4 (A0403) | 28 | 17.86 | 500 | + | HSIL | CIN 3 | 2 | |
| 1-5 (B0401) | 33 | 33.27 | 1,000 | + | HSIL | CIN 3 | 5 | |
| 1-6 (B0402) | 27 | 22.31 | 1,000 | + | HSIL | CIN 3 | 6 | |
| 1-7 (B0403) | 34 | 25.85 | 1,000 | + | HSIL | CIN 3 | 5 | |
| 1-8 (C0201) | 34 | 32.74 | 1,500 | + | HSIL | CIN 3 | 3 | |
| 1-9 (C0401) | 25 | 21.88 | 1,500 | + | ASC-US | CIN 3 | 5 | |
| 1-10 (C0501) | 33 | 23.71 | 1,500 | + | HSIL | CIN 3 | 3 | |
| Phase 2a | ||||||||
| 2-1 (D0201) | 39 | 26.31 | 1,000 | + | HSIL | CIN 3 | 3 | |
| 2-2 (D0401) | 47 | 18.14 | 1,000 | + | ASC-US | CIN 3 | 2 | |
| 2-3 (D0402) | 27 | 23.46 | 1,000 | + | ASC-US | CIN 3 | 4 | |
| 2-4 (D0501) | 37 | 20.57 | 1,000 | + | Negative | CIN 3 | 7 | |
| 2-5 (D0502) | 47 | 24.91 | 1,000 | + | Negative | CIN 3 | 3 | |
| 2-6 (D0503) | 25 | 16.82 | 1,000 | + | ASC-H | CIN 3 | 6 | |
| 2-7 (D0504) | 32 | 18.82 | 1,000 | + | ASC-US | CIN 3 | 4 | |
| 2-8 (D0505) | 30 | 22.43 | 1,000 | + | ASC-H | CIN 3 | 3 | |
| 2-9 (D0506) | 30 | 20.02 | 1,000 | + | LSIL | CIN 3 | 3 | |
ASC-H, atypical squamous cells, cannot exclude; ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; BMI, body mass index; HSIL, high-grade squamous intraepithelial lesion; HPV, human papillomavirus; LSIL, Low-grade squamous intraepithelial lesion; RCI, Reid Colposcopic Index.